Novartis generics arm files for MS biosimilar, challenging Biogen; Pluristem shortens name
Novartis’ generics arm Sandoz said it has submitted applications for a multiple sclerosis and Crohn’s disease biosimilar.
The drug is a biosimilar for Biogen’s Tysabri, known generically as natalizumab. According to Sandoz, in patients with relapsing-remitting MS, the biosimilar matched Tysabri in both efficacy and safety. Its BLA for the biosimilar has been accepted by both US and EU authorities, Sandoz said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.